<DOC>
	<DOCNO>NCT00230074</DOCNO>
	<brief_summary>This study evaluate safety clinical effect 4 oral dos TCH346 compare placebo patient mild mild moderate stage ALS .</brief_summary>
	<brief_title>A Long-term Extension Study TCH346 Placebo Administered Once Daily Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This study evaluate safety clinical effect 4 oral dos TCH346 compare placebo patient mild mild moderate stage ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Completed original protocol , Study No . CTCH346A2211 Be capable satisfying requirement extension protocol must sign informed consent nature extension protocol fully explain Exclusion criterion describe original protocol remain applicable extension protocol Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ; ALS</keyword>
</DOC>